17:38 , Nov 9, 2018 |  BC Week In Review  |  Clinical News

ViiV's fostemsavir maintains virologic suppression at week 48 in Phase III for HIV

ViiV Healthcare Ltd. (Brentford, U.K.) said fostemsavir plus optimized background therapy maintained virologic suppression of less than 40 copies/mL from week 24 to 48 in 54% of heavily treatment-experienced patients with HIV-1 infection in the...
04:48 , Nov 3, 2017 |  BC Week In Review  |  Clinical News

ViiV's HIV candidate fostemsavir meets in Phase III

ViiV Healthcare Ltd. (Brentford, U.K.) said oral fostemsavir (GSK3684934) (formerly BMS-663068) met the primary endpoint in the Phase III BRIGHTE trial to treat heavily treatment-experienced patients with HIV-1 infection. In the trial's randomized cohort, fostemsavir...
23:27 , Oct 27, 2017 |  BC Extra  |  Clinical News

ViiV's HIV candidate meets in Phase III

ViiV Healthcare Ltd. (Brentford, U.K.) said oral fostemsavir (GSK3684934) met the primary endpoint in the Phase III BRIGHTE trial to treat heavily treatment-experienced patients with HIV-1 infection. In the trial's randomized cohort, fostemsavir led to...
02:48 , Dec 19, 2015 |  BC Extra  |  Company News

BMS divests HIV pipeline to ViiV

Bristol-Myers Squibb Co. (NYSE:BMY) said it will divest its discovery-stage, preclinical and clinical HIV assets to ViiV Healthcare, an HIV-focused JV majority-owned by GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). The companies struck separate deals for late and...
07:00 , Jul 27, 2015 |  BC Week In Review  |  Clinical News

BMS-663068 regulatory update

FDA granted breakthrough therapy designation to Bristol-Myers’ BMS-663068 to treat HIV-1 infection in combination with other antiretroviral agents in heavily treatment-experienced adults. The HIV-1 attachment inhibitor that binds directly to HIV-1 gp120 is in a...
07:00 , Jun 29, 2015 |  BC Week In Review  |  Company News

Bristol-Myers infectious news

Bristol-Myers said it will discontinue drug discovery in virology and cut about 100 jobs as part of an ongoing R&D reorganization announced in 2013. The company said the change will not affect its clinical-stage and...
01:23 , Jun 26, 2015 |  BC Extra  |  Company News

BMS ending virology discovery, building Cambridge hub

Bristol-Myers Squibb Co. (NYSE:BMY) said it will discontinue drug discovery in virology as part of an ongoing R&D reorganization. The company said the change will not affect its clinical-stage and marketed virology products. BMS will...
07:00 , Mar 23, 2015 |  BC Week In Review  |  Clinical News

BMS-663068: Additional Phase IIb data

Additional data from the double-blind Phase IIb AI438011 trial in 251 evaluable treatment-experienced patients with HIV-1 infection showed that 61-82% of patients receiving BMS-663068 as an add-on to Isentress raltegravir plus Viread tenofovir achieved a...
07:00 , Mar 10, 2014 |  BC Week In Review  |  Clinical News

BMS-663068: Phase IIb data

A double-blind Phase IIb trial in treatment-experienced patients with HIV-1 infection showed that all doses of BMS-663068 as an add-on to raltegravir plus tenofovir met the primary endpoint of response defined as HIV-1 RNA <50...
00:51 , Mar 6, 2014 |  BC Extra  |  Clinical News

Bristol-Myers reports HIV data for BMS-663068

Bristol-Myers Squibb Co. (NYSE:BMY) reported data from a Phase IIb trial evaluating BMS-663068 as add-on treatment for HIV-1 infection. In 251 treatment-experienced patients in the intent-to-treat population, BMS-663068 as add-on to raltegravir and tenofovir led...